Sixty nine full HTAs on 20 ultra rare disease therapies were identified across 9 markets including Scotland (SMC), Wales (AWMSG), France (HAS), Germany (G-BA), Italy (UVEF), Spain (AQuAS and SESCS), Portugal (INFARMED), Netherlands (ZiNL) and Poland (AHTAPol). These 20 therapies span 17 ultra-orphan disease indications, mostly hereditary disorders, including: Adrenal cortical carcinoma (2 HTAs on Lysodren); Anthracycline extravasation (3 Savene); Atypical hemolytic uremic syndrome 1 (2 Soliris); Congenital bile acid synthesis defect type 1 and 2 (1 Orphacol); 3) Fabry disease (3 Fabrazyme and 4 Replagal); 4) Familial transthyretin amyloidosis (3 Vyndaqel); 5) Gaucher disease type 1 and 3 (2 Vpriv, 1 Zavesca and 1 Cerezyme); Hunter syndrome (4 Elaprase); Lambert-Eaton myasthenic syndrome (2 Firdapse); Mucopolysaccharidosis type 1 and 6 (4 Aldurazyme, 2 Elaprase and 1 Naglazyme); Niemann-Pick disease type C (1 Zavesca); Paroxysmal nocturnal haemoglobinuria (6 Soliris); Pulmonary arterial hypertension (10 Revatio, 7 Volibris, 5 Tracleer, 2 Opsumit and 1 Thelin); and Tyrosinemia type 1 (1 Orfadin).
No clear trend was identified over the years regarding reimbursement decisions granted. Although the number of HTAs resulting in a reimbursement recommendation, including those with a restriction, was always greater than those that were not recommended for reimbursement. In order, France then Scotland, Wales, Spain and the Netherlands had the most HTAs on ultraorphan disease therapies. The number of HTAs from French agency HAS greatly outweighed any other agency with 22 HTAs receiving a positive decision (3 with restriction). It is important to note that these HTAs represent both original submissions and re-evaluations of already reimbursed therapies. By doing this HAS is able to monitor the long-term efficacy of therapies and update the level of reimbursement according to a drug's actual benefit. The 2 UK agencies SMC (Scotland) and AWMSG (Wales) tended to grant more restricted or negative recommendations than positive recommendations. This stark difference to France may partly be due to differences in evidence requirements. Until recently, HAS did not require economic evidence when evaluating therapies for reimbursement. Whereas for SMC and AWMSG, economic and budget impact evidence is mandatory. Both INFARMED (Portugal) and AQuAS (Spain) perform HTAs but do not render reimbursement recommendations.
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As health care budgets become more strained, ultra-orphan disease therapies priced at a premium have come under increased scrutiny from HTA agencies and payers to demonstrate value for money. In order to achieve optimal market access, manufacturers must consider costs, utilization and long-term real-world evidence which can be captured through a registry. Utilizing registry data helps to influence public policy, ensuring patient access to necessary treatments and sustainable reimbursement.
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As ultra-orphan disease therapies are often some of the most expensive drugs on the market, reimbursement decisions were predominately hinged on clinical benefit, cost and budget impact rather than cost-effectiveness. Clinical evidence against placebo was most frequent and was largely accepted across agencies. Data on quality of life is becoming increasingly important with a moderate to high number of HTAs identified with quality of life data. Thirteen of the 69 HTAs received criticism for not submitting quality of life evidence for their product. Only 2 of the 3 patient access schemes proposed to the SMC were accepted. In 8 of 9 HTAs that resulted in a negative reimbursement decision, evaluating committees criticised that a robust economic analysis was not presented. Assumptions applied in these analyses were often considered uncertain. In 7 of these HTAs, clinical evidence was also scrutinised not only for the lack of clinical benefit demonstrated (through the primary outcome) but also in respect to the lack of comparators and quality of life measures used within clinical trials presented. In most circumstances where the drug evaluated was first in market, data comparing to local standard of care, even if non-pharmaceutical, was often required.
In 19 of the 50 HTAs that were either recommended or recommended with restricted access, evaluation committees requested the submitting manufacturer for additional real-world evidence on efficacy and safety through ongoing monitoring of patients. For 9 of these reports, it was confirmed that a registry was already in place. In 2 HTAs, the evaluating committee requested the manufacturer to set up a registry. For remaining 7 HTAs, the method adopted to meet monitoring requirements was not specified. 
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